Independent fund research. Built on SEC filings.

How we research funds

ETF · Health Care Sector · Franklin Templeton

Franklin Genomic Advancements ETF (HELX)

Ticker HELX · Since 2020-02-25 · · Holdings as of Jun 30, 2026

Expense ratio
0.5%$50/yr per $10k
5-yr return
−3.8%annualized
1-yr return
+25.9%as of Dec 2025
Net assets
$27.9Mall share classes
Holdings
63

Bottom line

Is HELX a good fund? The bottom line

HELX is an actively managed health care sector ETF from Franklin Templeton.

Its expense ratio is 0.5% — about $50 a year on every $10,000 invested, cheaper than 81% of health care sector funds we track.

It returned +25.9% over one year, −3.8% a year over five years (as of Dec 31, 2025, per its prospectus).

With $27.9 million in net assets and 63 holdings, its largest position is Guardant Health Inc (9.1%) and the top 10 make up 47.1% of the portfolio.

What stands out

  • Low cost: cheaper than 81% of health care sector peers

What to watch

  • 5-year return in the bottom quarter of its category
  • Small fund ($27.9 million) — small funds are likelier to close

Updated Nov 19, 2026

What HELX invests in

Capital appreciation.

Under normal market conditions, the Fund invests at least 80% of its net assets in equity securities of companies that are relevant to the Funds investment theme of genomic advancements. The Fund invests predominantly in common stock. Companies relevant to the Funds investment theme of genomic advancements are those that the investment manager believes are substantially focused on and/or are expected to substantially benefit from extending and enhancing the quality of human and other life (e.g., animals) by incorporating technological and scientific developments, improvements and advancements in the field of genomics into their business, such as by offering new products or services that rely on genetic engineering, gene therapy, genome analysis, DNA sequencing, synthesis or instrumentation. These companies may include those that research, develop, produce, manufacture or significantly…

From the fund's prospectus (filed Jul 27, 2026).

HELX performance

Fund calendar-year total returns, 2021–2025 2021: +9.7%; 2022: −37.9%; 2023: +1.2%; 2024: −5.1%; 2025: +25.9% +9.7% 2021 −37.9% 2022 +1.2% 2023 −5.1% 2024 +25.9% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
HELX+25.9%−3.8%—
Health Care Sector median+14.5%+4.2%+7.9%

Source: Fund prospectus, as of Dec 31, 2025

Full HELX performance history →

What HELX costs

On a $10,000 investment, HELX's 0.5% expense ratio costs about $50 a year. The prospectus estimates $629 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.

See the full HELX fee table →

HELX top 10 holdings

#Holding% of fund
1Guardant Health Inc GH9.09%
2Natera Inc NTRA7.46%
3Krystal Biotech Inc KRYS6.33%
4Ligand Pharmaceuticals Inc LGND4.62%
5Adaptive Biotechnologies Corp ADPT3.99%
6United Therapeutics Corp UTHR3.51%
7Bridgebio Pharma Inc BBIO3.50%
8Eli Lilly & Company LLY2.95%
9Twist Bioscience Corp TWST2.85%
10Vertex Pharmaceuticals Inc VRTX2.75%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 47.1% of the fund. See all top 25 holdings and asset mix →

Alternatives to HELX

More funds like HELX →

HELX FAQ

What is the expense ratio of HELX?
HELX's expense ratio is 0.5%, which works out to about $50 a year for every $10,000 invested. The prospectus estimates total costs of $629 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is HELX a good investment?
It depends on your goals, but the data points to: low cost: cheaper than 81% of health care sector peers; 5-year return in the bottom quarter of its category; small fund ($27.9 million) — small funds are likelier to close. This is general information, not personalized advice.
What does HELX hold?
HELX's largest holdings are Guardant Health Inc (9.1%), Natera Inc (7.5%), Krystal Biotech Inc (6.3%), Ligand Pharmaceuticals Inc (4.6%), Adaptive Biotechnologies Corp (4.0%). It holds 63 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is HELX's 5-year return?
HELX returned −3.8% a year over the five years ending Dec 31, 2025. Past performance does not guarantee future results.
Who manages HELX?
HELX is offered by Franklin Templeton through Franklin Templeton ETF Trust.